PDF
ePub
Citation
Print
Abstract
Non-alcoholic fatty liver disease (NAFLD) has been characterized by a wide spectrum of liver damage that spans from steatosis, non-alcoholic steatohepatitis (NASH), cryptogenic liver cirrhosis and even to hepatocellular carcinoma. During the last few years, investigation has focused on the group of NASH, a relatively aggressive form of liver disease. One of the main reasons for the explosion of information on NASH provided by clinical and basic science studies is that its risk factors, such as obesity, type II diabetes mellitus, and dyslipidemia, are those of the most prevalent morbidities in the general population. Recently, obesity and type II diabetes mellitus have reached epidemic proportions in Korea. The pathogenesis of NASH is multifactorial. Insulin resistance and increased fatty acid may be important factors in the accumulation of hepatocellular fat, whereas oxidant stress, lipid peroxidation, mitochondrial dysfunction, and adenosine triphosphate (ATP) depletion may be important causes of hepatocellular injury in the steatotic liver. Because not all steatotic livers progress to NASH, some other environmental factors or combined genetic factors are thought to be required for progression to NASH and fibrosis. Life style modification continues to be the cornerstone of therapy. Exercise and diet may be effective means of improving insulin sensitivity. Some insulin-sensitizing agents and antioxidants have shown to be promising. Despite recent gains in the understanding of this disease entity, a number of unresolved issues related to its natural history, pathogenesis and treatment remain to be elucidated.
Figures and Tables
References
1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980. 55:434–438.
2. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis. 2004. 24:3–20.
3. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003. 37:1202–1219.
4. Youssef WI, McCullough AJ. Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol. 2002. 16:733–747.
5. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Rizzetto R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003. 37:917–923.
6. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Sheridan MJ, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002. 123:745–750.
7. Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano PL, Moreno-Otero R, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol. 2000. 33:716–724.
8. Talwalkar JA. Motion-all patients with NASH need to have a liver biopsy: arguments for the motion. Can J Gastroenterol. 2002. 16:718–721.
9. Laurin J. Motion-all patients with NASH need to have a liver biopsy: arguments against the motion. Can J Gastroenterol. 2002. 16:722–726.
10. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989. 20:594–598.
11. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994. 107:1103–1109.
12. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999. 29:664–669.
13. Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol. 1995. 20:127–130.
14. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Boparai M, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl. 2001. 7:797–801.
15. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Rizzetto M, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002. 123:134–140.
16. Caldwell SH, Crespo DM, Kang HS, Al Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology. 2004. 127:Suppl 1. S97–S103.
17. Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology. 2002. 123:375–378.
18. Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, Shiratori K, et al. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J Gastroenterol. 2004. 39:1215–1218.
19. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002. 36:1349–1354.
21. Propst A, Propst T, Judmaier G, Vogel W. Prognosis in nonalcoholic steatohepatitis. Gastroenterology. 1995. 108:1607.
22. Rothman DL, Magnusson I, Katz LD, Shulman RG, Shulman GI. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science. 1991. 254:573–576.
23. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest. 1992. 90:1323–1323.
24. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell. 2001. 104:517–529.
25. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995. 95:2409–2415.
26. Barzilai N, Wang J, Massilon D, Vuguin P, Hawkins M, Rossetti L. Leptin selectively decreases visceral adiposity and enhances insulin action. J Clin Invest. 1997. 100:3105–3110.
27. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002. 346:1221–1231.
28. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001. 281:G1135–G1139.
29. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Deugnier Y, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology. 1999. 117:1155–1163.
30. Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem. 2002. 277:17377–17380.
31. Mensenkamp AR, Teusink B, Baller JF, Wolters H, Havinga R, Kuipers F, et al. Mice expressing only the mutant APOE3Leiden gene show impaired VLDL secretion. Arterioscler Thromb Vasc Biol. 2001. 21:1366–1372.
32. Mensenkamp AR, Havekes LM, Romijn JA, Kuipers F. Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. J Hepatol. 2001. 35:816–822.
33. Leung GK, Veniant MM, Kim SK, Zlot CH, Raabe M, Young SG, et al. A deficiency of microsomal triglyceride transfer protein reduces apolipoprotein B secretion. J Biol Chem. 2000. 275:7515–7520.
34. Bernard S, Touzet S, Personne I, Lapras V, Bondon PJ, Moulin P, et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia. 2000. 43:995–999.
35. Vendemiale G, Grattagliano I, Caraceni P, Caraccio G, Domenicali M, Altomare E, et al. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. Hepatology. 2001. 33:808–815.
36. Baffy G, Zhang C-Y, Glickman JN, Lowell BB. Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. Hepatology. 2002. 35:753–761.
37. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000. 108:9–13.
38. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Fargion S, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002. 122:274–280.
39. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology. 2002. 35:762–771.
40. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Sato N, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 2002. 122:1399–1410.
41. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol. 2004. 41:943–949.
43. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002. 13:84–89.
44. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004. 40:46–54.
45. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Lazar MA, et al. The hormone resistin links obesity to diabetes. Nature. 2001. 409:307–312.
46. Wolf G. Insulin resistance and obesity: resistin, a hormone secreted by adipose tissue. Nutr Rev. 2004. 62:389–394.
47. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. Obes Res. 1998. 6:Suppl 2. 51S–209S.
48. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heymsfield SB, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999. 281:235–242.
49. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol. 2003. 98:926–930.
50. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology. 2002. 123:882–932.
51. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999. 131:281–303.
52. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990. 347:645–650.
53. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 1999. 354:141–148.
54. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003. 38:1008–1017.
55. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Hoofnagle JH, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004. 39:188–196.
56. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000. 6:998–1003.
57. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002. 359:2072–2077.
58. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000. 136:734–738.
59. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001. 96:2711–2717.
60. Colell A, Garcia-Ruiz C, Morales A, Ballesta A, Ookhtens M, Fernandez-Checa JC, et al. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-L-methionine. Hepatology. 1997. 26:699–708.
61. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos. 2000. 28:1270–1273.
62. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Colin P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004. 39:770–778.
63. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998. 98:2088–2093.
64. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol. 1999. 31:384.
65. Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Memik F, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003. 17:713–718.
66. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, England JD, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002. 137:581–585.
XML Download